2022
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Jessel S, Weiss SA, Austin M, Mahajan A, Etts K, Zhang L, Aizenbud L, Perdigoto AL, Hurwitz M, Sznol M, Herold KC, Kluger HM. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Frontiers In Oncology 2022, 12: 836859. PMID: 35350573, PMCID: PMC8958012, DOI: 10.3389/fonc.2022.836859.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaCombination immune checkpoint inhibitorsCell carcinomaClinical experienceSelect casesIncidence of hypophysitisInstitution's clinical experienceYale Cancer CenterObjective response rateAdrenal axis hormonesFree testosterone levelsMerkel cell carcinomaHigh rateMultiple tumor typesCheckpoint inhibitorsPituitary axesReal-world practiceFree testosteroneMedian timeMelanoma patientsOverall incidencePituitary functionTreatment delayAxis hormones
2021
The State of Morning Report in the Current Healthcare Landscape: a National Survey of Internal Medicine Program Directors
Lessing JN, McGarry K, Schiffman F, Austin M, Hepokoski M, Keniston A, Tammaro D, Finn KM. The State of Morning Report in the Current Healthcare Landscape: a National Survey of Internal Medicine Program Directors. Journal Of General Internal Medicine 2021, 37: 1665-1672. PMID: 34585310, PMCID: PMC8477724, DOI: 10.1007/s11606-021-07010-1.Peer-Reviewed Original Research
2020
Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record.
Zayac AS, Hilliard RW, Olszewski AJ, Pelcovits A, Reagan JL, Hsu A, Riley D, Austin M, Ollila TA. Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record. Rhode Island Medical Journal (2013) 2020, 103: 78-83. PMID: 33003686.Peer-Reviewed Original ResearchTargeting Innate Immunity to Treat Cancer
Austin M, Kluger H. Targeting Innate Immunity to Treat Cancer. Cancers 2020, 12: 2723. PMID: 32977403, PMCID: PMC7597964, DOI: 10.3390/cancers12102723.Peer-Reviewed Original Research
2019
Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis
Austin M, Quesenberry PJ, Ventetuolo CE, Liang O, Reagan JL. Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis. Clinical Lymphoma Myeloma & Leukemia 2019, 19: 593-597. PMID: 31262666, PMCID: PMC6814397, DOI: 10.1016/j.clml.2019.05.009.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionSecondary myelofibrosisOverall survivalMF patientsPrimary myelofibrosisSingle-center retrospective chart reviewGroup 5 pulmonary hypertensionImpact of PHInfluence of PHPresence of PHChronic obstructive pulmonary diseaseRetrospective patient databaseIntermediate-risk patientsRetrospective chart reviewObstructive pulmonary diseaseBone marrow fibrosisPathogenesis of myelofibrosisMF cohortRoutine echoConstitutional symptomsChart reviewRisk patientsPulmonary diseaseTransthoracic echoMarrow fibrosis